C9 抗体 (FITC)
Our Local Distributor
北京 101111
Quick Overview for C9 抗体 (FITC) (ABIN1106799)
抗原
See all C9 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
交叉反应 （详细）
- Species reactivity (tested):Human, horse, pig
-
纯化方法
- Protein G
-
亚型
- IgG2a
-
-
anti-Complement Component C9 (C9) (AA 191-220), (Center) antibody
C9 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal RB33918 unconjugated
anti-Complement Component C9 (C9) (AA 22-265) antibodyC9 适用: 人 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Complement Component C9 (C9) (AA 136-512) antibodyC9 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Complement Component C9 (C9) (AA 139-519) antibody (APC)C9 适用: 兔 WB, IHC 宿主: 豚鼠 Polyclonal APC
anti-Complement Component C9 (C9) (AA 191-220) antibodyC9 适用: 人 WB, IHC, ELISA 宿主: 兔 Polyclonal unconjugated
anti-Complement Component C9 (C9) (AA 336-554) antibodyC9 适用: 大鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Complement Component C9 (C9) (AA 205-216) antibodyVerified C9 适用: 人 WB, ELISA 宿主: 山羊 Polyclonal unconjugated
anti-Complement Component C9 (C9) (AA 184-411) antibodyC9 适用: 人 WB, ICC, IHC (p), IF 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
浓度
- 0.1 mg/mL
-
缓冲液
- PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin
-
储存液
- Sodium azide
-
注意事项
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C
-
储存方法
- Store at 2 - 8 °C.
-
-
- C9 (Complement Component C9 (C9))
-
别名
- Complement C9
-
背景
- The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 Molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.Synonyms: Complement 9, Complement component C9
-
UniProt
- P02748
-
途径
- Complement System
抗原
-
